Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bandana Sharan"'
Autor:
Chaitanya Kumar, Jasmine Bagga, Srikanth Chiliveru, Sakshi Kohli, Asmi Bharadwaj, Minish Jain, Shriram Inamdar, Bandana Sharan
Publikováno v:
Future Science OA, Vol 5, Iss 10 (2019)
Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma show
Externí odkaz:
https://doaj.org/article/3b2cbe4a66e74825bf8562d54b9e9f87
Autor:
Sakshi Kohli, Venkata Sathya Suresh Attili, Ashok K. Vaid, P.P. Bapsy, Bandana Sharan, Minish Mahendra Jain, Chaitanya Kumar, Jagan Mohan, Srikanth Chiliveru
Publikováno v:
Immunotherapy. 9:889-897
Aim: A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7663f221f62b538eab93094c7f57db6
https://doi.org/10.2217/imt-2017-0064
https://doi.org/10.2217/imt-2017-0064
Autor:
Chaitanya, Kumar, Sakshi, Kohli, Srikanth, Chiliveru, Poonamalle Parthasarathy, Bapsy, Minish, Jain, Venkata Sathya, Suresh Attili, Jagan, Mohan, Ashok K, Vaid, Bandana, Sharan
Publikováno v:
Immunotherapy. 9(11)
A retrospective survival benefit analysis of APCEDENSubjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::617955076933a6d28c5ea05f040356b4
https://pubmed.ncbi.nlm.nih.gov/28838282
https://pubmed.ncbi.nlm.nih.gov/28838282
Autor:
P.P. Bapsy, Bandana Sharan, Ashok K. Vaid, Minish Mahendra Jain, Sakshi Kohli, Chaitanya Kumar, Venkata Sathya Suresh Attili
Publikováno v:
Journal of biosciences. 42(1)
The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb23a32348a9dec4d258620ef431cbf9
https://pubmed.ncbi.nlm.nih.gov/28229976
https://pubmed.ncbi.nlm.nih.gov/28229976
Autor:
Rajeev Patrick Das, Minish Mahendra Jain, Venkata Sathya Suresh Attili, Ashok K. Vaid, Chaitanya Kumar, Bharath Rangarajan, Bandana Sharan, Shyam Aggarwal, Mala Srivastava, P.P. Bapsy, Sundaram Subramanian
Publikováno v:
Cytotherapy. 16:234-244
Background aims A phase II clinical trial of an autologous dendritic cell (DC) formulation for the management of refractory solid malignant tumors was conducted across six sites in India with an objective to study safety and efficacy. Methods A total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38624d37e3497a88084796829d3c250
https://doi.org/10.1016/j.jcyt.2013.11.013
https://doi.org/10.1016/j.jcyt.2013.11.013